Natera Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Natera de 69.4% y 12.3% por año respectivamente. Se prevé que el BPA crezca en un 67.5% al año. Se espera que la rentabilidad financiera sea de 0.3% en 3 años.

Información clave

69.4%

Tasa de crecimiento de los beneficios

67.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.3%
Tasa de crecimiento de los ingresos	12.3%
Rentabilidad financiera futura	0.3%
Cobertura de analistas	Good
Última actualización	26 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158

Nov 15

Recent updates

Subdued Growth No Barrier To Natera, Inc. (NASDAQ:NTRA) With Shares Advancing 25%

Nov 19

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158

Nov 15

Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds

Oct 31

Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 18

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Jul 05

Natera: Overdue For A Breather

Jun 03

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

May 12

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Aug 07

Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

May 16

Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

Apr 18

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:NTRA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	2,107	13	181	299	18
12/31/2025	1,793	-151	20	151	19
12/31/2024	1,631	-197	-76	120	17
9/30/2024	1,532	-215	-44	25	N/A
6/30/2024	1,361	-292	-118	-56	N/A
3/31/2024	1,209	-365	-197	-139	N/A
12/31/2023	1,083	-435	-286	-247	N/A
9/30/2023	989	-499	-311	-270	N/A
6/30/2023	931	-512	-387	-343	N/A
3/31/2023	868	-546	-419	-375	N/A
12/31/2022	820	-548	-479	-432	N/A
9/30/2022	776	-546	-498	-449	N/A
6/30/2022	723	-576	-492	-438	N/A
3/31/2022	667	-546	-453	-398	N/A
12/31/2021	625	-472	-385	-335	N/A
9/30/2021	565	-408	-354	-310	N/A
6/30/2021	505	-315	-280	-252	N/A
3/31/2021	449	-258	-244	-222	N/A
12/31/2020	391	-230	-202	-183	N/A
9/30/2020	362	-189	-139	-124	N/A
6/30/2020	342	-153	-117	-104	N/A
3/31/2020	330	-126	-79	-67	N/A
12/31/2019	302	-125	-68	-63	N/A
9/30/2019	286	-121	-66	-61	N/A
6/30/2019	273	-128	-76	-72	N/A
3/31/2019	262	-129	-107	-103	N/A
12/31/2018	258	-128	-74	-71	N/A
9/30/2018	243	-144	-88	-86	N/A
6/30/2018	233	-142	N/A	-94	N/A
3/31/2018	223	-137	N/A	-72	N/A
12/31/2017	210	-138	N/A	-98	N/A
9/30/2017	207	-128	N/A	-99	N/A
6/30/2017	205	-126	N/A	-92	N/A
3/31/2017	205	-121	N/A	-99	N/A
12/31/2016	213	-100	N/A	-74	N/A
9/30/2016	221	-81	N/A	-49	N/A
6/30/2016	212	-72	N/A	-42	N/A
3/31/2016	205	-69	N/A	-35	N/A
12/31/2015	190	-70	N/A	-38	N/A
9/30/2015	187	-46	N/A	-23	N/A
6/30/2015	189	-28	N/A	0	N/A
3/31/2015	179	-6	N/A	13	N/A
12/31/2014	159	-5	N/A	10	N/A
9/30/2014	133	-11	N/A	-4	N/A
3/31/2014	78	-29	N/A	-20	N/A
12/31/2013	55	-37	N/A	-24	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que NTRA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que NTRA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que NTRA sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (12.3% al año) de NTRA crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 12.3% al año) de NTRA crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de NTRA sea baja dentro de 3 años (0.3%).

Natera Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2026

No longer forecast to breakeven

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158

Consensus estimates of losses per share improve by 20%

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Recent updates

Natera Announces Medicare Coverage for Prospera™? in Single Lung Transplant Recipients

Forecast to breakeven in 2026

Federal Court Jury Issues Unanimous Verdict That Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

Independent Director recently sold US$1.5m worth of stock

Independent Director exercised options and sold US$4.6m worth of stock

Subdued Growth No Barrier To Natera, Inc. (NASDAQ:NTRA) With Shares Advancing 25%

No longer forecast to breakeven

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158

Co-Founder & Director notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Natera Announces Completion of Signatera Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

Natera, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds

Now 22% overvalued after recent price rise

Co-Founder & Director notifies of intention to sell stock

Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price

Natera, Inc. Announces New Data from the GALAXY Arm of the Ongoing Circulate-Japan Trial at the 2024 Congress of the European Society for Medical Oncology in Barcelona, Spain

Now 23% overvalued after recent price rise

Consensus estimates of losses per share improve by 20%

Forecast to breakeven in 2026

Co-Founder & Executive Chairman exercised options to buy US$22m worth of stock.

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

Natera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

CEO & Director notifies of intention to sell stock

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Natera, Inc. Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer

CEO & Director notifies of intention to sell stock

Natera, Inc. Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients

Natera: Overdue For A Breather

New minor risk - Insider selling

Secretary & Chief Legal Officer notifies of intention to sell stock

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

Price target increased by 9.0% to US$113

Natera, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.56 loss per share (vs US$1.23 loss in 1Q 2023)

Natera, Inc. to Report Q1, 2024 Results on May 09, 2024

Natera, Inc., Annual General Meeting, Jun 12, 2024

CEO & Director notifies of intention to sell stock

Now 20% undervalued

Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation

Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (Modern) A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer

Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?

Natera: Capitalizing On The Positive Momentum Of Personalized Medicine

Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™? in Stage II Colorectal Cancer

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 11%

Is Natera (NASDAQ:NTRA) A Risky Investment?

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 12% to US$86.94

Natera, Inc. Provides Earnings Guidance for the Year 2024

Natera, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Independent Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Natera, Inc. Announces New Study Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Provides Update on Ravgen Trial

Natera, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2023

Natera Announces New Study Highlighting the Benefits of Signatera's Unique Method of Quantifying ctDNA

Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)

Natera, Inc. Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

Natera, Inc. Raises Revenue Guidance for the Full Year 2023

Is Natera (NASDAQ:NTRA) A Risky Investment?

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Natera, Inc. Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Natera's RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight in Chronic Kidney Disease

Co-Founder & Director notifies of intention to sell stock